Prognostic Significance of HER 2 and HER 4 Coexpression in Childhood Medulloblastoma 1

Recent in vitro studies of the epidermal growth factor receptor (EGFR) family have revealed complex signaling interactions involving the produc lion ofligand-mediatedheterodimers synergisticforthetransformation of cells in vitro. In a series of7O patients with childhood medulloblastoma, we haveusedimmunohistochemistry and Westernblottinganalysisto inves tigate the expression patterns of all four EGFR family members (EGFR, HER2, HER3, and HER4) and heregulin-a, a ligand for the HER) and HER4receptors.The majorityof cases expressedtwo or more receptor proteins; coexpression ofthe HER2 and HER4 receptors occurred in 54%. Expression of the ligand heregulin-a was detected in 31% of tumors. To investigate whether coexpression results in receptor heterodimerization, we havealso performedimmunoprecipitation analysisof proteinextracts from primary tumors, and we demonstrate various patterns of receptor interaction including between HER2 and HER4. In multivariate25-yearsurvivalanalysiswith clinicopathological dis easefeatures, noindividual receptoror heregulin-aachievedsignificance. In contrast, when considered together in the multivariate model, coax pression of HER2 and HER4 demonstrated independent prognostic sig nificance (P = 0.006). These data suggest the hypothesis that HER2-HER4 receptorheterodimerization is of particularbiologicalsignificancein this disease, and this report is the first to demonstrate potential clinical significance ofEGFR family heterodimerization in human cancer Finally, we have also analyzedexpressionof the AP.2 transcriptionfactor1mph rated in the positive regulation of HER2 and HER3 gene transcription in malignant cells and reveal an association between AP-2 expression and not only HER2 and HER3, but also HER4 leveis in medulloblastoma primary tumors.

[1]  M. Busslinger,et al.  Deregulated expression of PAX 5 in medulloblastoma , 2005 .

[2]  V. Schirrmacher,et al.  EGF receptor in neoplasia and metastasis , 1993, Cancer and Metastasis Reviews.

[3]  W. Gullick,et al.  The type I growth factor receptors in human breast cancer , 2004, Breast Cancer Research and Treatment.

[4]  E. Jaros,et al.  Mitotic percentage index: a new prognostic factor for childhood medulloblastoma. , 1997, European journal of cancer.

[5]  I. Ellis,et al.  C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. , 1996, British Journal of Cancer.

[6]  M. Greene,et al.  Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  L. Akslen,et al.  Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. , 1996, Cancer research.

[8]  H. Gattamaneni,et al.  An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. , 1996, Archives of disease in childhood.

[9]  T. van Raaij,et al.  Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. , 1996, Oncogene.

[10]  H Sugimura,et al.  Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. , 1996, Cancer research.

[11]  R. Harkins,et al.  Heregulin Activation of Extracellular Acidification in Mammary Carcinoma Cells Is Associated with Expression of HER2 and HER3 (*) , 1995, The Journal of Biological Chemistry.

[12]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[13]  A. Aguzzi,et al.  Deregulated expression of PAX5 in medulloblastoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[15]  R. Perry,et al.  Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. , 1995, British Journal of Cancer.

[16]  T. Williams,et al.  The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  T. Hongo,et al.  Chromosome analysis of brain tumors in childhood , 1994, Genes, chromosomes & cancer.

[18]  P. Mitchell,et al.  Cell type-specific regulation of expression of transcription factor AP-2 in neuroectodermal cells. , 1994, Developmental biology.

[19]  Y. Yarden,et al.  Brain neurons and glial cells express Neu differentiation factor/heregulin: a survival factor for astrocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Waldman,et al.  Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma. , 1994, Genomics.

[21]  W. Dougall,et al.  The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. , 1994, Oncogene.

[22]  L. Cantley,et al.  A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.

[23]  Y. Yarden,et al.  Neu Differentiation Factors: A Family of Alternatively Spliced Neuronal and Mesenchymal Factors , 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[24]  H. Hurst,et al.  Transcriptional regulation of the c-erbB-3 gene in human breast carcinoma cell lines. , 1993, Oncogene.

[25]  R. Gelber,et al.  Prognostic factors in medulloblastoma, including DNA ploidy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Waterfield,et al.  Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system , 1993, Nature.

[27]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Seidman,et al.  Expression of the HER‐2/neu proto‐oncogene in serous ovarian neoplasms , 1992, Cancer.

[29]  D. Barnes,et al.  Expression of the ERBB3 gene product in breast cancer. , 1992, British Journal of Cancer.

[30]  I. Ellis,et al.  Production and characterization of a polyclonal antibody to the c‐erbB‐3 protein: Examination of c‐erbB‐3 protein expression in adenocarcinomas , 1992, The Journal of pathology.

[31]  D. Goeddel,et al.  Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.

[32]  Yosef Yarden,et al.  Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells , 1992, Cell.

[33]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[34]  A. Ullrich,et al.  Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Trent,et al.  Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. , 1991, Cancer research.

[36]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[37]  Y. Yarden,et al.  Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. , 1990, Biochemistry.

[38]  L. Becker,et al.  Posterior fossa medulloblastoma in childhood: treatment results and a proposal for a new staging system. , 1990, International journal of radiation oncology, biology, physics.

[39]  G. Plowman,et al.  Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Greene,et al.  Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function , 1990, Cell.

[41]  H. Bloom,et al.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). , 1990, European journal of cancer.

[42]  W. Wara,et al.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. , 1990, Journal of neurosurgery.

[43]  W. McGuire,et al.  HER-2/neu oncogene protein and prognosis in breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  V. Brown,et al.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts , 1989, Cell.

[45]  T. Fleming,et al.  Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. , 1989, Oncogene.

[46]  M. Sela,et al.  Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. , 1988, Journal of the National Cancer Institute.

[47]  D. Bigner,et al.  Structural chromosomal abnormalities in human medulloblastoma. , 1988, Cancer genetics and cytogenetics.

[48]  A. Ullrich,et al.  Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells , 1987, Cell.

[49]  J. Cohen,et al.  Stage- and tissue-specific expression of the neu oncogene in rat development. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[50]  J. Trent,et al.  Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants , 1987, Molecular and cellular biology.

[51]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[52]  J. Minna,et al.  Immunohistochemical localization of the immunodominant differentiation antigen lacto-N-fucopentaose III in normal adult and fetal tissues. , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[53]  D.,et al.  Regression Models and Life-Tables , 2022 .